TomlinsonBHuMZhangYChanPLiuZM.Alirocumab for the treatment of hypercholesterolemia. Expert Opin Biol Ther. 2017;17:633-643. doi:10.1080/14712598.2017.1305354
2.
ShuklaAKMehaniR.Safety and efficacy of alirocumab: a meta analysis of 12 randomized controlled trials. J Family Med Prim Care. 2019;8:2249-2257. doi:10.4103/jfmpc.jfmpc_406_19
3.
RobinsonJGFarnierMKrempfM, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1489-1499. doi:10.1056/NEJMoa1501031
4.
NaranjoCABustoUSellersEM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-245. doi:10.1038/clpt.1981.154
5.
NitscheCJJamiesonNLerchMMMayerleJV.Drug induced pancreatitis. Best Pract Res Clin Gastroenterol. 2010;24:143-155. doi:10.1016/j.bpg.2010.02.002
6.
Sadr-AzodiOMattssonFBexliusTSLindbladMLagergrenJLjungR.Association of oral glucocorticoid use with an increased risk of acute pancreatitis: a population-based nested case-control study. JAMA Intern Med. 2013;173:444-449. doi:10.1001/jamainternmed.2013.2737
7.
SinghSChangHYRichardsTMWeinerJPClarkJMSegalJB.Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med. 2013;173:534-539. doi:10.1001/jamainternmed.2013.2720
8.
LanghiCLe MayCGmyrV, et al. PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion. Biochem Biophys Res Commun. 2009;390:1288-1293. doi:10.1016/j.bbrc.2009.10.138
9.
CariouBSi-TayebKLe MayC. Role of PCSK9 beyond liver involvement. Curr Opin Lipidol. 2015;26:155-161. doi:10.1097/MOL.0000000000000180
